Yes, some GLP-1 agonists, like Wegovy, are FDA-approved specifically for weight loss
The regulatory and coverage context is different
[4] [6] Understanding how tirzepatide works is essential when considering discontinuation, as its effects on glucose metabolism, gastric motility, and appetite regulation do not persist indefinitely after stopping treatment
Semaglutide's primary side effects are gastrointestinalnausea, vomiting, diarrhea, and constipationthat typically emerge when doses increase and diminish over 48 weeks as the body adjusts
After attaining at least 5% weight loss at 12 weeks, our responder population demonstrated a highly variable longer term response to both exenatide and diet
doi: 10.1186/s12967-025-06635-8 50